var data={"title":"Vasodilator therapy in chronic mitral regurgitation","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Vasodilator therapy in chronic mitral regurgitation</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/vasodilator-therapy-in-chronic-mitral-regurgitation/contributors\" class=\"contributor contributor_credentials\">William H Gaasch, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/vasodilator-therapy-in-chronic-mitral-regurgitation/contributors\" class=\"contributor contributor_credentials\">Catherine M Otto, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/vasodilator-therapy-in-chronic-mitral-regurgitation/contributors\" class=\"contributor contributor_credentials\">Susan B Yeon, MD, JD, FACC</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/vasodilator-therapy-in-chronic-mitral-regurgitation/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Jan 15, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with severe mitral regurgitation (MR), especially those with heart failure, may experience a dramatic hemodynamic improvement during intravenous vasodilator therapy [<a href=\"https://www.uptodate.com/contents/vasodilator-therapy-in-chronic-mitral-regurgitation/abstract/1\" class=\"abstract_t\">1</a>]. Based in part upon these observations, it would seem reasonable to consider the use of oral vasodilators in selected patients with chronic MR.</p><p>Candidates for such therapy could include certain patients who are not candidates for surgery, particularly those with end-stage decompensated MR, and those with compensated MR in whom surgery is not yet indicated. In the latter group, the goal of vasodilator therapy might be to reduce the rate of progression of the hemodynamic burden and, therefore, to delay the onset of symptoms and the need for corrective surgery.</p><p>An overview of the management of chronic MR is presented separately. (See <a href=\"topic.htm?path=management-of-chronic-primary-mitral-regurgitation\" class=\"medical medical_review\">&quot;Management of chronic primary mitral regurgitation&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">DETERMINANTS OF REGURGITANT VOLUME</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The volume of mitral regurgitant volume (MRV) is determined hydraulically by two factors:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The duration (D) and magnitude of the systolic pressure gradient across the valve; the latter is determined by the difference between the left ventricular and left atrial systolic pressures (LVP and LAP). It can be especially important to consider the duration factor in the evaluation of patients with mitral valve prolapse [<a href=\"https://www.uptodate.com/contents/vasodilator-therapy-in-chronic-mitral-regurgitation/abstract/2\" class=\"abstract_t\">2</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The mitral regurgitant orifice area (MROA).</p><p/><p>The following formula can be used to estimate the MRV [<a href=\"https://www.uptodate.com/contents/vasodilator-therapy-in-chronic-mitral-regurgitation/abstract/3\" class=\"abstract_t\">3</a>]:</p><p> &#160;MRV &#160;= &#160;MROA &#160;x &#160;constant &#160;x &#160;D &#160;x &#160;sq rt (LVP &#160;- &#160;LAP)</p><p>Since the magnitude and duration of the pressure gradient and the orifice area can vary, it is possible to explain the effects of hemodynamic interventions and therapies on the regurgitant volume. Depending upon the clinical setting, vasodilators can decrease or increase regurgitant flow:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Drugs with vasodilator activity, such as <a href=\"topic.htm?path=nitroprusside-drug-information\" class=\"drug drug_general\">nitroprusside</a>, angiotensin converting enzyme inhibitors, and angiotensin II receptor blockers, can reduce the regurgitant flow in symptomatic patients and those with heart failure, especially when due to papillary muscle dysfunction [<a href=\"https://www.uptodate.com/contents/vasodilator-therapy-in-chronic-mitral-regurgitation/abstract/1,4,5\" class=\"abstract_t\">1,4,5</a>]. This beneficial effect is mediated by a decrease in ventricular and annular size, which reduces the effective regurgitant orifice area; there may be little or no change in the pressure gradient across the mitral valve [<a href=\"https://www.uptodate.com/contents/vasodilator-therapy-in-chronic-mitral-regurgitation/abstract/5\" class=\"abstract_t\">5</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Venodilators may have the opposite effect in patients with mitral valve prolapse and some with hypertrophic cardiomyopathy, augmenting mitral regurgitant flow via an influence on ventricular size and mitral leaflet coaptation, and duration of the MR [<a href=\"https://www.uptodate.com/contents/vasodilator-therapy-in-chronic-mitral-regurgitation/abstract/1\" class=\"abstract_t\">1</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Venodilation can also increase the regurgitant volume in patients with fixed orifice MR (eg, rheumatic or calcific disease) [<a href=\"https://www.uptodate.com/contents/vasodilator-therapy-in-chronic-mitral-regurgitation/abstract/1\" class=\"abstract_t\">1</a>]. In this setting, venodilation can reduce pulmonary venous pressure, leading to a fall in left atrial pressure that may be greater than the reduction in LV systolic pressure, thereby increasing the pressure gradient favoring regurgitation. By contrast, a pure reduction in systolic pressure would reduce MR, especially in the hypertensive patient.</p><p/><p>Arterial dilation reduces LV systolic pressure and afterload. LV afterload is usually normal in compensated and increased in decompensated MR [<a href=\"https://www.uptodate.com/contents/vasodilator-therapy-in-chronic-mitral-regurgitation/abstract/6-8\" class=\"abstract_t\">6-8</a>], but in primary MR, afterload is not a determinant of regurgitant flow [<a href=\"https://www.uptodate.com/contents/vasodilator-therapy-in-chronic-mitral-regurgitation/abstract/1\" class=\"abstract_t\">1</a>]. </p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">CLINICAL STUDIES</span></p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Acute vasodilator therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The effect of acute vasodilator therapy in patients with chronic mitral regurgitation (MR) has primarily been evaluated in symptomatic patients with heart failure with variable results that depend upon the drug used and the mechanism of MR.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Short-term vasodilator therapy with intravenous <a href=\"topic.htm?path=nitroprusside-drug-information\" class=\"drug drug_general\">nitroprusside</a> is an effective and reliable treatment for patients with severe MR, especially those with secondary MR due to dilated cardiomyopathy [<a href=\"https://www.uptodate.com/contents/vasodilator-therapy-in-chronic-mitral-regurgitation/abstract/1,9-12\" class=\"abstract_t\">1,9-12</a>]. Intravenous nitroprusside decreases left ventricular (LV) end-diastolic pressure and volume and regurgitant flow, while increasing forward stroke volume and cardiac index [<a href=\"https://www.uptodate.com/contents/vasodilator-therapy-in-chronic-mitral-regurgitation/abstract/1,9-12\" class=\"abstract_t\">1,9-12</a>]. The LV ejection fraction is usually unchanged, as there is a roughly equivalent reduction in regurgitant flow and increase in forward flow [<a href=\"https://www.uptodate.com/contents/vasodilator-therapy-in-chronic-mitral-regurgitation/abstract/1\" class=\"abstract_t\">1</a>]. <a href=\"topic.htm?path=hydralazine-drug-information\" class=\"drug drug_general\">Hydralazine</a>, which is primarily an arterial dilator, also increases forward flow but does not decrease ventricular end-diastolic pressure or volume [<a href=\"https://www.uptodate.com/contents/vasodilator-therapy-in-chronic-mitral-regurgitation/abstract/13,14\" class=\"abstract_t\">13,14</a>]. The benefits are most pronounced when the MR is secondary to LV dysfunction.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The effects of acute administration of angiotensin converting enzyme (ACE) inhibitors or nitrates appear to be less consistent. Although the regurgitant volume may decrease, there is usually a reduction or no change in the cardiac index [<a href=\"https://www.uptodate.com/contents/vasodilator-therapy-in-chronic-mitral-regurgitation/abstract/15-20\" class=\"abstract_t\">15-20</a>]. Furthermore, for the reasons noted above, the acute administration of <a href=\"topic.htm?path=isosorbide-dinitrate-drug-information\" class=\"drug drug_general\">isosorbide dinitrate</a> in patients with rheumatic MR can produce an increase in regurgitant flow [<a href=\"https://www.uptodate.com/contents/vasodilator-therapy-in-chronic-mitral-regurgitation/abstract/20\" class=\"abstract_t\">20</a>]. </p><p/><p class=\"headingAnchor\" id=\"H5\"><span class=\"h2\">Chronic vasodilator therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Chronic vasodilator therapy is indicated in <strong>symptomatic</strong> patients who are not candidates for surgery. The evidence of benefit is best in patients with secondary (functional) MR due to LV dysfunction [<a href=\"https://www.uptodate.com/contents/vasodilator-therapy-in-chronic-mitral-regurgitation/abstract/14,21,22\" class=\"abstract_t\">14,21,22</a>]. </p><p>There are no published studies that support the hypothesis that vasodilator therapy is beneficial in <strong>asymptomatic</strong> patients with chronic primary MR [<a href=\"https://www.uptodate.com/contents/vasodilator-therapy-in-chronic-mitral-regurgitation/abstract/1,3,23-25\" class=\"abstract_t\">1,3,23-25</a>]. The results from small, mostly uncontrolled studies of varying causes of MR are less impressive than would have been predicted from the effects of short-term intravenous therapy [<a href=\"https://www.uptodate.com/contents/vasodilator-therapy-in-chronic-mitral-regurgitation/abstract/4,14,21-24\" class=\"abstract_t\">4,14,21-24</a>]. Although the regurgitant volume may fall, the average change is generally modest and there is substantial interpatient variability in response.</p><p>The following observations illustrate the range of findings in symptomatic patients with secondary (functional) MR due to heart failure. </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In an initial report, 15 symptomatic patients (New York Heart Association [NYHA] class III to IV), (<a href=\"image.htm?imageKey=CARD%2F52683\" class=\"graphic graphic_table graphicRef52683 \">table 1</a>) were treated with oral <a href=\"topic.htm?path=hydralazine-drug-information\" class=\"drug drug_general\">hydralazine</a> and followed for 13 months [<a href=\"https://www.uptodate.com/contents/vasodilator-therapy-in-chronic-mitral-regurgitation/abstract/14\" class=\"abstract_t\">14</a>]. The etiology of MR was mixed. Eight patients achieved a sustained symptomatic improvement, while the remaining patients had either intolerable side effects or failed to improve.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A combination of high-dose <a href=\"topic.htm?path=lisinopril-drug-information\" class=\"drug drug_general\">lisinopril</a> (average 55 <span class=\"nowrap\">mg/day</span> up to 80 <span class=\"nowrap\">mg/day)</span> and <a href=\"topic.htm?path=isosorbide-dinitrate-drug-information\" class=\"drug drug_general\">isosorbide dinitrate</a> (average 286 <span class=\"nowrap\">mg/day</span> up to 480 <span class=\"nowrap\">mg/day)</span> was administered for 12 months to 19 patients with severe secondary MR and NYHA class III to IV heart failure (<a href=\"image.htm?imageKey=CARD%2F52683\" class=\"graphic graphic_table graphicRef52683 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/vasodilator-therapy-in-chronic-mitral-regurgitation/abstract/21\" class=\"abstract_t\">21</a>]. For the group as a whole, there was a significant reduction in NYHA class (3 versus 1.6) and hospitalizations for heart failure, and an increase in peak oxygen consumption. MR reduced to grade 0 to 1 in eight patients and remained at grade 3 to 4 in 11; MR responders had a significantly smaller initial LV end-diastolic diameter compared with nonresponders (6.4 versus 7 cm) and a diameter &le;6.8 cm had a sensitivity and specificity of 83 percent for predicting MR improvement.</p><p/><p>Two small randomized trials have evaluated the efficacy of ACE inhibitors in asymptomatic patients with chronic primary MR:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a randomized controlled trial, the effect of <a href=\"topic.htm?path=captopril-drug-information\" class=\"drug drug_general\">captopril</a> (25 mg three times daily) was compared with placebo in a study of 32 largely asymptomatic patients (NYHA class I to II) (<a href=\"image.htm?imageKey=CARD%2F52683\" class=\"graphic graphic_table graphicRef52683 \">table 1</a>) with chronic rheumatic MR [<a href=\"https://www.uptodate.com/contents/vasodilator-therapy-in-chronic-mitral-regurgitation/abstract/23\" class=\"abstract_t\">23</a>]. After six months, there was no difference in systolic arterial pressure, LV volume, or ejection fraction between the two groups. It was concluded that captopril had no effect on LV size or performance in patients with severe MR but mild or no symptoms.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a second controlled trial, 23 asymptomatic patients with moderate MR and normal LV function were assigned to <a href=\"topic.htm?path=lisinopril-drug-information\" class=\"drug drug_general\">lisinopril</a> or placebo for one year [<a href=\"https://www.uptodate.com/contents/vasodilator-therapy-in-chronic-mitral-regurgitation/abstract/24\" class=\"abstract_t\">24</a>]. The MR fraction fell by 6.4 percent with lisinopril compared with a 3.7 percent increase with placebo. However, there was no change in left atrial or LV dimensions.</p><p/><p>Data about the efficacy of angiotensin II receptor blockers in chronic MR in humans are limited and suggest only modest benefit [<a href=\"https://www.uptodate.com/contents/vasodilator-therapy-in-chronic-mitral-regurgitation/abstract/4\" class=\"abstract_t\">4</a>]. In an animal study of new onset MR, the administration of <a href=\"topic.htm?path=irbesartan-drug-information\" class=\"drug drug_general\">irbesartan</a> for three months reduced systemic vascular resistance compared with no therapy, but had no effect on cardiac output or progressive LV enlargement and remodeling [<a href=\"https://www.uptodate.com/contents/vasodilator-therapy-in-chronic-mitral-regurgitation/abstract/26\" class=\"abstract_t\">26</a>].</p><p>In summary, benefit has primarily been found in patients with moderate to severe symptoms with secondary MR due to LV dysfunction [<a href=\"https://www.uptodate.com/contents/vasodilator-therapy-in-chronic-mitral-regurgitation/abstract/14,21,22\" class=\"abstract_t\">14,21,22</a>], while asymptomatic patients with primary valve disease appear to exhibit little or no improvement [<a href=\"https://www.uptodate.com/contents/vasodilator-therapy-in-chronic-mitral-regurgitation/abstract/23,24,27\" class=\"abstract_t\">23,24,27</a>]. </p><p class=\"headingAnchor\" id=\"H996459666\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-cardiac-valve-disease\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Cardiac valve disease&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h1\">RECOMMENDATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In chronic mitral regurgitation (MR), intravenous vasodilator therapy can provide significant hemodynamic improvement, but long-term oral vasodilator therapy is not uniformly beneficial. Nevertheless, some recommendations can be made:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Short-term vasodilator therapy with intravenous <a href=\"topic.htm?path=nitroprusside-drug-information\" class=\"drug drug_general\">nitroprusside</a> is an effective and reliable treatment for symptomatic patients with severe MR, especially those with acute MR or secondary MR due to dilated cardiomyopathy. (See <a href=\"#H4\" class=\"local\">'Acute vasodilator therapy'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>There are no published studies that support the hypothesis that vasodilator therapy is beneficial in <strong>asymptomatic</strong> patients with chronic primary MR. (See <a href=\"#H5\" class=\"local\">'Chronic vasodilator therapy'</a> above.)</p><p/><p>However, angiotensin converting enzyme (ACE) inhibitors or angiotensin II receptor blockers can be given when there is another indication for their use such as hypertension, left ventricular (LV) dysfunction, or diabetes [<a href=\"https://www.uptodate.com/contents/vasodilator-therapy-in-chronic-mitral-regurgitation/abstract/3\" class=\"abstract_t\">3</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Chronic vasodilator therapy is indicated in <strong>symptomatic</strong> patients who are not candidates for surgery. The evidence of benefit is best in patients with secondary (functional) MR due to LV dysfunction. Treatment of such patients should consist of optimal medical therapy of heart failure and, in appropriate patients, cardiac resynchronization therapy. With respect to ACE inhibitors <span class=\"nowrap\">and/or</span> angiotensin II receptor blockers, the dose titration and monitoring schedules are the same as for heart failure due to LV systolic dysfunction in the absence of moderate to severe MR. (See <a href=\"#H5\" class=\"local\">'Chronic vasodilator therapy'</a> above and <a href=\"topic.htm?path=overview-of-the-therapy-of-heart-failure-with-reduced-ejection-fraction\" class=\"medical medical_review\">&quot;Overview of the therapy of heart failure with reduced ejection fraction&quot;</a> and <a href=\"topic.htm?path=use-of-angiotensin-converting-enzyme-inhibitors-in-heart-failure-with-reduced-ejection-fraction\" class=\"medical medical_review\">&quot;Use of angiotensin converting enzyme inhibitors in heart failure with reduced ejection fraction&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In symptomatic patients with rheumatic MR, there is little potential to induce a change in the regurgitant orifice area, and the therapeutic goal should be a reduction in pulmonary venous pressure and arterial systolic pressure, especially if the patient is hypertensive. Thus, an ACE inhibitor with a diuretic, a beta blocker, <a href=\"topic.htm?path=hydralazine-drug-information\" class=\"drug drug_general\">hydralazine</a>, or calcium channel blocker can be used.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In hypertensive patients with mitral valve prolapse, a pure reduction in LV end diastolic volume can promote prolapse and increase the regurgitation. The primary goal in hypertensive patients should be to reduce arterial pressure. Thus, a beta blocker, perhaps in combination with a calcium channel blocking agent, can be used. </p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/vasodilator-therapy-in-chronic-mitral-regurgitation/abstract/1\" class=\"nounderline abstract_t\">Levine HJ, Gaasch WH. Vasoactive drugs in chronic regurgitant lesions of the mitral and aortic valves. J Am Coll Cardiol 1996; 28:1083.</a></li><li><a href=\"https://www.uptodate.com/contents/vasodilator-therapy-in-chronic-mitral-regurgitation/abstract/2\" class=\"nounderline abstract_t\">Topilsky Y, Michelena H, Bichara V, et al. Mitral valve prolapse with mid-late systolic mitral regurgitation: pitfalls of evaluation and clinical outcome compared with holosystolic regurgitation. Circulation 2012; 125:1643.</a></li><li><a href=\"https://www.uptodate.com/contents/vasodilator-therapy-in-chronic-mitral-regurgitation/abstract/3\" class=\"nounderline abstract_t\">Gaasch WH, Aurigemma GP. Inhibition of the renin-angiotensin system and the left ventricular adaptation to mitral regurgitation. J Am Coll Cardiol 2002; 39:1380.</a></li><li><a href=\"https://www.uptodate.com/contents/vasodilator-therapy-in-chronic-mitral-regurgitation/abstract/4\" class=\"nounderline abstract_t\">Dujardin KS, Enriquez-Sarano M, Bailey KR, et al. Effect of losartan on degree of mitral regurgitation quantified by echocardiography. Am J Cardiol 2001; 87:570.</a></li><li><a href=\"https://www.uptodate.com/contents/vasodilator-therapy-in-chronic-mitral-regurgitation/abstract/5\" class=\"nounderline abstract_t\">Rosario LB, Stevenson LW, Solomon SD, et al. The mechanism of decrease in dynamic mitral regurgitation during heart failure treatment: importance of reduction in the regurgitant orifice size. J Am Coll Cardiol 1998; 32:1819.</a></li><li><a href=\"https://www.uptodate.com/contents/vasodilator-therapy-in-chronic-mitral-regurgitation/abstract/6\" class=\"nounderline abstract_t\">Wisenbaugh T, Spann JF, Carabello BA. Differences in myocardial performance and load between patients with similar amounts of chronic aortic versus chronic mitral regurgitation. J Am Coll Cardiol 1984; 3:916.</a></li><li><a href=\"https://www.uptodate.com/contents/vasodilator-therapy-in-chronic-mitral-regurgitation/abstract/7\" class=\"nounderline abstract_t\">Corin WJ, Monrad ES, Murakami T, et al. The relationship of afterload to ejection performance in chronic mitral regurgitation. Circulation 1987; 76:59.</a></li><li><a href=\"https://www.uptodate.com/contents/vasodilator-therapy-in-chronic-mitral-regurgitation/abstract/8\" class=\"nounderline abstract_t\">Zile MR, Gaasch WH, Levine HJ. Left ventricular stress-dimension-shortening relations before and after correction of chronic aortic and mitral regurgitation. Am J Cardiol 1985; 56:99.</a></li><li><a href=\"https://www.uptodate.com/contents/vasodilator-therapy-in-chronic-mitral-regurgitation/abstract/9\" class=\"nounderline abstract_t\">Chatterjee K, Parmley WW, Swan HJ, et al. Beneficial effects of vasodilator agents in severe mitral regurgitation due to dysfunction of subvalvar apparatus. Circulation 1973; 48:684.</a></li><li><a href=\"https://www.uptodate.com/contents/vasodilator-therapy-in-chronic-mitral-regurgitation/abstract/10\" class=\"nounderline abstract_t\">Goodman DJ, Rossen RM, Holloway EL, et al. Effect of nitroprusside on left ventricular dynamics in mitral regurgitation. Circulation 1974; 50:1025.</a></li><li><a href=\"https://www.uptodate.com/contents/vasodilator-therapy-in-chronic-mitral-regurgitation/abstract/11\" class=\"nounderline abstract_t\">Harshaw CW, Grossman W, Munro AB, McLaurin LP. Reduced systemic vascular resistance as therapy for severe mitral regurgitation of valvular origin. Ann Intern Med 1975; 83:312.</a></li><li><a href=\"https://www.uptodate.com/contents/vasodilator-therapy-in-chronic-mitral-regurgitation/abstract/12\" class=\"nounderline abstract_t\">Sasayama S, Ohyagi A, Lee JD, et al. Effect of the vasodilator therapy in regurgitant valvular disease. Jpn Circ J 1982; 46:433.</a></li><li><a href=\"https://www.uptodate.com/contents/vasodilator-therapy-in-chronic-mitral-regurgitation/abstract/13\" class=\"nounderline abstract_t\">Greenberg BH, Massie BM, Brundage BH, et al. Beneficial effects of hydralazine in severe mitral regurgitation. Circulation 1978; 58:273.</a></li><li><a href=\"https://www.uptodate.com/contents/vasodilator-therapy-in-chronic-mitral-regurgitation/abstract/14\" class=\"nounderline abstract_t\">Greenberg BH, DeMots H, Murphy E, Rahimtoola SH. Arterial dilators in mitral regurgitation: effects on rest and exercise hemodynamics and long-term clinical follow-up. Circulation 1982; 65:181.</a></li><li><a href=\"https://www.uptodate.com/contents/vasodilator-therapy-in-chronic-mitral-regurgitation/abstract/15\" class=\"nounderline abstract_t\">Wisenbaugh T, Essop R, Rothlisberger C, Sareli P. Effects of a single oral dose of captopril on left ventricular performance in severe mitral regurgitation. Am J Cardiol 1992; 69:348.</a></li><li><a href=\"https://www.uptodate.com/contents/vasodilator-therapy-in-chronic-mitral-regurgitation/abstract/16\" class=\"nounderline abstract_t\">R&ouml;thlisberger C, Sareli P, Wisenbaugh T. Comparison of single dose nifedipine and captopril for chronic severe mitral regurgitation. Am J Cardiol 1994; 73:978.</a></li><li><a href=\"https://www.uptodate.com/contents/vasodilator-therapy-in-chronic-mitral-regurgitation/abstract/17\" class=\"nounderline abstract_t\">Sch&ouml;n HR, Schr&ouml;ter G, Bl&ouml;mer H, Sch&ouml;mig A. Beneficial effects of a single dose of quinapril on left ventricular performance in chronic mitral regurgitation. Am J Cardiol 1994; 73:785.</a></li><li><a href=\"https://www.uptodate.com/contents/vasodilator-therapy-in-chronic-mitral-regurgitation/abstract/18\" class=\"nounderline abstract_t\">Sniderman AD, Marpole DG, Palmer WH, Fallen EL. Response of the left ventricle to nitroglycerin in patients with and without mitral regurgitation. Br Heart J 1974; 36:357.</a></li><li><a href=\"https://www.uptodate.com/contents/vasodilator-therapy-in-chronic-mitral-regurgitation/abstract/19\" class=\"nounderline abstract_t\">Elkayam U, Roth A, Kumar A, et al. Hemodynamic and volumetric effects of venodilation with nitroglycerin in chronic mitral regurgitation. Am J Cardiol 1987; 60:1106.</a></li><li><a href=\"https://www.uptodate.com/contents/vasodilator-therapy-in-chronic-mitral-regurgitation/abstract/20\" class=\"nounderline abstract_t\">Jeang MK, Petrovich LJ, Adyanthaya AV, Alexander J. Effects of isosorbide dinitrate on rheumatic and non-rheumatic mitral regurgitation. Tex Heart Inst J 1986; 13:453.</a></li><li><a href=\"https://www.uptodate.com/contents/vasodilator-therapy-in-chronic-mitral-regurgitation/abstract/21\" class=\"nounderline abstract_t\">Levine AB, Muller C, Levine TB. Effects of high-dose lisinopril-isosorbide dinitrate on severe mitral regurgitation and heart failure remodeling. Am J Cardiol 1998; 82:1299.</a></li><li><a href=\"https://www.uptodate.com/contents/vasodilator-therapy-in-chronic-mitral-regurgitation/abstract/22\" class=\"nounderline abstract_t\">Sch&ouml;n HR, Schr&ouml;ter G, Barthel P, Sch&ouml;mig A. Quinapril therapy in patients with chronic mitral regurgitation. J Heart Valve Dis 1994; 3:303.</a></li><li><a href=\"https://www.uptodate.com/contents/vasodilator-therapy-in-chronic-mitral-regurgitation/abstract/23\" class=\"nounderline abstract_t\">Wisenbaugh T, Sinovich V, Dullabh A, Sareli P. Six month pilot study of captopril for mildly symptomatic, severe isolated mitral and isolated aortic regurgitation. J Heart Valve Dis 1994; 3:197.</a></li><li><a href=\"https://www.uptodate.com/contents/vasodilator-therapy-in-chronic-mitral-regurgitation/abstract/24\" class=\"nounderline abstract_t\">Marcotte F, Honos GN, Walling AD, et al. Effect of angiotensin-converting enzyme inhibitor therapy in mitral regurgitation with normal left ventricular function. Can J Cardiol 1997; 13:479.</a></li><li><a href=\"https://www.uptodate.com/contents/vasodilator-therapy-in-chronic-mitral-regurgitation/abstract/25\" class=\"nounderline abstract_t\">Iung B, Gohlke-B&auml;rwolf C, Tornos P, et al. Recommendations on the management of the asymptomatic patient with valvular heart disease. Eur Heart J 2002; 23:1253.</a></li><li><a href=\"https://www.uptodate.com/contents/vasodilator-therapy-in-chronic-mitral-regurgitation/abstract/26\" class=\"nounderline abstract_t\">Perry GJ, Wei CC, Hankes GH, et al. Angiotensin II receptor blockade does not improve left ventricular function and remodeling in subacute mitral regurgitation in the dog. J Am Coll Cardiol 2002; 39:1374.</a></li><li><a href=\"https://www.uptodate.com/contents/vasodilator-therapy-in-chronic-mitral-regurgitation/abstract/27\" class=\"nounderline abstract_t\">Borer JS, Sharma A. Drug Therapy for Heart Valve Diseases. Circulation 2015; 132:1038.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 8152 Version 8.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H6\"><span>RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">DETERMINANTS OF REGURGITANT VOLUME</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">CLINICAL STUDIES</a><ul><li><a href=\"#H4\" id=\"outline-link-H4\">Acute vasodilator therapy</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">Chronic vasodilator therapy</a></li></ul></li><li><a href=\"#H996459666\" id=\"outline-link-H996459666\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"CARD/8152|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=CARD/52683\" class=\"graphic graphic_table\">- NYHA and other classifications of cardiovascular disability</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=management-of-chronic-primary-mitral-regurgitation\" class=\"medical medical_review\">Management of chronic primary mitral regurgitation</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-the-therapy-of-heart-failure-with-reduced-ejection-fraction\" class=\"medical medical_review\">Overview of the therapy of heart failure with reduced ejection fraction</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-cardiac-valve-disease\" class=\"medical medical_society_guidelines\">Society guideline links: Cardiac valve disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=use-of-angiotensin-converting-enzyme-inhibitors-in-heart-failure-with-reduced-ejection-fraction\" class=\"medical medical_review\">Use of angiotensin converting enzyme inhibitors in heart failure with reduced ejection fraction</a></li></ul></div></div>","javascript":null}